Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.93 USD | +2.51% | -4.84% | +76.25% |
Mar. 26 | Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating | MT |
Mar. 18 | Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.25% | 1.34B | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |
- Stock
- Equities
- Stock Spyre Therapeutics, Inc. - Nasdaq
- News Spyre Therapeutics, Inc.
- Sector Update: Health Care Carried Higher by Surging Biotechs